Trials / Completed
CompletedNCT02947841
The Effectiveness of Alternating Stimulation in Preventing Tolerance in Essential Tremor Patients
The Effectiveness of Alternating Ventral Intermediate Nucleus Deep Brain Stimulation Parameters in Preventing Tolerance in Essential Tremor Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Oregon Health and Science University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the hypothesis that alternating DBS parameters on a weekly basis will prevent tolerance to stimulation and thus waning of benefit, compared with non-alternating stimulation. The primary endpoint will be preserved tremor control with the alternating group compared with standard treatment using the Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS). Key secondary endpoints will be preserved activities of daily living measures as well as preserved tremor control as quantified by motion sensor data. This study has one primary aim: To determine if alternating DBS stimulation parameters on a weekly basis will be superior at preserving tremor control compared with usual stimulation (non-alternating stimulation) in ET patients with VIM DBS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Alternating stimulation | Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above. |
| OTHER | Placebo | The control cohort will receive Setting A but Setting B will be identical to Setting A. |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-06-01
- Completion
- 2017-07-01
- First posted
- 2016-10-28
- Last updated
- 2018-09-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02947841. Inclusion in this directory is not an endorsement.